| Previous Close | 87.76 |
| Open | 88.51 |
| Day High | 91.27 |
| Day Low | 87.01 |
| 52-Week High | 151.02 |
| 52-Week Low | 11.28 |
| Volume | 884,327 |
| Average Volume | 1.27M |
| Market Cap | 4.39B |
| PE | -23.06 |
| EPS | -3.9 |
| Moving Average 50 Days | 117.35 |
| Moving Average 200 Days | 97.56 |
| Change | 2.17 |
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
GlobeNewswire Inc.
Mar 09, 2026 9:42 PM GMT
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively MINNEAPOLI
Celcuity To Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 9:01 PM GMT
MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founde
Celcuity Appoints Charles Romp to its Board of Directors
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of D